The package insert, which is jointly authored by the U.S. Food and Drug Administration and the manufacturer of the drug, is a summary of all of the preclinical and clinical data accumulated during the successful development of a new drug. Despite the role of the package insert in the safe practice of medicine, prescribers often minimize, overlook, or misunderstand its importance, suggesting a gap in their training. An anonymous, three-question survey was administered to third year medical students (N = 34) from two medical schools to assess how well they had been educated about the evidence-based origin, purpose, and implications of the package insert. The results indicate a deficiency in their medical education, and the authors contrast the student responses with the facts. These results underscore the need to revise medical school curricula to provide future prescribers with more education about the importance of the package insert and the relationship between pharmaceutical companies, the U.S. Food and Drug Administration, and prescribers. (Journal of Psychiatric Practice 2014;20:284-290) 
Today, medications are a major therapeutic modality for most healthcare practitioners and their patients. Yet, as a result of lecturing around the country, one of the authors (S.H.P.) has been impressed with how few prescribers are aware of what goes into the development and approval of a new medication and its package insert. This deficiency seems to have grown as efforts have increased to limit the ability of pharmaceutical companies to educate healthcare providers about new medications. A discussion of the reason for these efforts is beyond the scope of this column. Never theless, to the authors' knowledge, no compensatory effort has been made to offset the loss of medical education that was in the past provided by pharmaceutical companies. In fact, the authors conducted searches of PubMed using the key terms package insert, package insert and medical education, product label, and product label and medical education. None of these searches yielded any articles that explained the origins, purpose, or basis for the package insert, that discussed how to educate healthcare professionals about the package insert, or that examined healthcare professionals' knowledge of the package insert. These results supported the need for this study.
For physicians, the initial education about pharmacology and medications used to treat most patients occurs during the first 2 years of medical school. These courses are often taught by pharmacologists who are usually research scientists with a specific focus and area of interest rather than practicing physicians. As a result, practical aspects of clinical pharmacology may not be covered in the basic pharmacology modules in medical school.
The package insert, which comes in the box with every prescription, contains guidance for using the medication in clinical practice (Table 1) . Prescribers are therefore supposed to be knowledgeable about it.
However, it is unclear what medical students learn about the package insert. To address this question, the authors administered a survey to third year medical students at two different institutions who had completed the pharmacology training offered by their medical schools and were doing their basic psychiatry rotation. 
Methods

Patient Counseling Information
Also known as a "black box warning." This warning may be applied to individual medications or to an entire class of medications based on adverse events shown to be associated with one or more of the drugs in the class. Its usual intent is to highlight for prescribers: 1) an adverse reaction so serious that it must be considered when prescribing, 2) a serious adverse reaction that can be prevented or its frequency reduced by using appropriate precautions, 3) that the FDA approved the drug with restrictions to ensure its safe use.
The reason(s) for prescribing the drug based on appropriately designed and executed positive clinical trials
The specific starting, target, and maximum doses of the medication for each of its indications, along with other relevant guidance for the general population Amount of active ingredient(s) in the various dosage form(s) of the drug (e.g., "1 mg, 2 mg, and 3 mg tablets")
Warnings not to use the drug in populations with a specific medical condition, or in combination with other drugs due to common serious adverse events Serious adverse effects ("serious" refers to adverse effects that can result in death or near death, hospitalization, birth defects, persistent incapacity, or other clinically significant adverse outcomes)
Most common adverse reactions (found in у 5% of patients and/or at least twice the incidence in patients receiving placebo)
Potentially clinically important pharmacodynamic and/or pharmacokinetic effects (e.g., effects on the cytochrome P450 enzyme system) Guidance for adjusting dose in special populations such as renally or hepatically impaired patients or pregnant or geriatric patients
What is known about the pharmacodynamics (e.g., mechanism of action) and pharmacokinetics (e.g., absorption, distribution, metabolism, excretion) of the drug A more detailed discussion of the drug's effectiveness in treating patients with the conditions for which the drug has a labeled indication A section directed toward the patient. It often uses a "frequently asked questions" format in which the most important information is conveyed to patients in simplified language. similar, they were combined. Some specific responses are also quoted in the results to enrich the data and convey the variety of responses received. The three survey questions were: 1. Who writes the package insert? 2. What is the basis for what is stated in the package insert? 3. If you are ever sued over the alleged misuse of a drug, why will the package insert generally be introduced as evidence in the case?
Results
There were no differences between the responses of the M.D. and D.O. students or between the groups that were administered the survey on different dates, nor was there any evidence that subsequent groups were influenced by the knowledge gained by earlier groups. Responses to each question generally fit into one of a few categories, as shown in Tables 2.1-2.3, and were weighted based on the number of times they were given. Responses were left as "standalone" when they did not fit in any clear category. When asked who writes the package insert, only 1 of 34 respondents definitively answered the question of authorship correctly, that the package insert is written jointly by the manufacturer of the specific drug and the U.S. Food and Drug Administration (FDA). The answer of one other respondent was close (see Table 2 .1). However, the vast majority (82%, 28/34) answered that the package insert was written solely by the manufacturer of the drug.
When asked about the basis for the information in the package insert, only 38% answered that the statements in the package insert are based on data from clinical trials, although many of the respondents appeared to be answering as if the question was about the purpose of the document. Nevertheless, the responses are colorful and reflect many common misperceptions, including the idea that the content of the package insert may be influenced by ulterior motives on the part of the pharmaceutical manufacturer to divert liability for patient adverse events to the prescriber. It is interesting to note that the students who responded that the FDA was the source for information in the package insert in Question 2 were not the same students who mentioned the FDA in Question 1.
The answers to Question 3 indicated that the respondents in general conceptualized the package insert as a kind of guidance document that the prescriber should know and use both to make good prescribing decisions and to convey information about the risks and benefits of a medication to patients. Although almost all of the respondents recognized the value of the package insert in providing guidance in prescribing and indicated that the physician has a duty to know the contents, only 15% of the responses referred to informed consent. Some of the responses implied a lack of appreciation for the amount of information (beyond data on side effects) in the package insert or for the depth of clinical trials data that support the statements in the document. The theme of manufacturers' wanting to divert liability for patient adverse events also appeared again in responses to this question.
Discussion
The package insert is a required component for the sale and distribution of prescribed pharmaceuticals and must provide information to guide the prescriber in the safe use of the medication in a manner that is unbiased and based upon objective data. It is also referred to as the product label, and a compilation of these labels makes up what is published under the title, the Physician's Desk Reference (PDR) © . 3 Although the manufacturer funds the clinical trials and finances the research that provides the information contained in the package insert, it is the FDA that guides the manufacturer in the drug development process and establishes and enforces the labeling requirements. The FDA does not regulate the practice of medicine, but rather the production and promotion of drugs and other forms of somatic therapy.
One purpose of the package insert is to promote the safe and effective use of the drug based on research conducted primarily in preclinical and clinical trials. Title 21 of the Code of Federal Regulations Part 310 (regarding new drugs) lists the expected contents of a package insert. 1 Table 1 presents and explains the minimal format included in most, if not all, modern package inserts.
Indications are the evidence-based reasons for which the drug can be used. The dosage and administration section is intended to provide the prescriber with information that will increase the likelihood of the effective and safe use of the drug. The information contained in this section is based on pharmaco-kinetic and pharmacodynamic data gathered in the preclinical and clinical drug development process.
Safety and tolerability issues are addressed in the sections titled contraindications, warning and precautions, adverse reactions, drug interactions, and use in special populations.
The package insert is revised as new information becomes available. Examples would be adding an indication after the manufacturer runs an additional successful clinical trial program for that indication or adding a black-box warning if adverse events due to a medication are reported after its release on the market or after new pharmacogenomic information becomes available. 4 The package insert is also used to regulate what the manufacturer can claim about a product. When a provider prescribes a drug for a purpose other than one of the stated indications in the package insert, it is an "off label use" of that approved medication. "Off label promotion" is when a manufacturer suggests a drug can be used for a condition that has not been indicated in the package insert. That means that sufficient data have not been presented for FDA evaluation to determine whether the medication is sufficiently efficacious in the new condition to outweigh any safety or tolerability concerns, which would be the basis for the FDA to approve a new indication in the product label for a medication. Allegations of "off label" promotion of drugs have in recent years led the FDA and other federal agencies to levy large fines against specific pharmaceutical companies.
Question 1: Who writes the package insert?
Only 1 of the 34 medical students definitively answered that the package insert is jointly authored Journal of Psychiatric Practice Vol. 20, No. 4
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Psychopharmacology "Research, but not necessarily based on the strongest evidence" "Drug information based on the company's research" "Clinical trials and post-marketing results" "To inform patients of side effects and adverse events compiled from safety studies/clinical trials" "FDA-directed warnings" "FDA rules and regulations" "FDA regulations on use and side effects" "Compliance with FDA guidelines/education" "List all intended purposes/adverse reactions of the drug" "Safety" "Reported adverse events" "To inform the patient about the drug and its adverse effects" "To give patient and physician information about the drug" "To help healthcare providers" "Prevent lawsuits against the drug company" "Legal awareness for patient" "Give warnings concerning side effects and remove liability from the company" "Remove liability from the pharmaceutical company and properly instruct physicians" "Differences between two specific medications"
*Some respondents appeared to answer as if the question concerned the purpose of the package insert. FDA: U.S. Food and Drug Administration 1 ). This knowledge gap likely contributed to the medical students' opinion that the package insert is used to divert liability for patient adverse events from the manufacturer to the prescriber. While prescribing outside the guidelines of the package insert may indeed expose prescribers to greater liability that is not inevitably the case nor is it the primary goal of the package insert. The advantage of prescribing in accordance with the package insert is the amount of evidence that supports the statements in the insert and the amount of scrutiny it has received. However, there are many "off label" uses that also have considerable evidence supporting them but that evidence has not been submitted to the FDA for approval of that new indication. The reason is often financial (e.g., the drug is off patent). For a drug to be approved for sale in the United States, a manufacturer must submit evidence to the FDA that the drug is efficacious in treating one or more indications and that its efficacy outweighs any "It provides the instructions on how to properly use the drug. This will be compared with our actions." "It is the accepted standard by which the medication should be used." "It provides the only objective data that specify the appropriate use of the drug for the consumer." "It guides the FDA-approved usage of the drug." "Because it is comprehensive about drug risks/benefits." "It is included with prescriptions." (standard of care implied) "It contains fundamental medical knowledge for use of the drug." "Because it is approved by the FDA (guidelines for drug use)." "If it shows the adverse effect, it helps cover the physician." "It generally protects the physician from being sued. If you go 'off label,' you are on the hook." "It will be used to put cause on the physician."
"It provides the published risks/benefits/potential outcomes of the medication and it is assumed that you are aware of those when prescribing." "Because as the prescribing physician, you are expected to know the adverse reactions to medications."
"Because it is the physician's duty to go over the patient insert with the patient."
"Prescribing physicians are responsible for knowing/warning about all adverse effects/content described." "It proves that the patient and the doctor knew about the adverse event." "To identify a side effect that you failed to mention to the patient." "Duty" "It contains all of the FDA guidelines." "Because it was there and there are instructions to read the insert." *8 = entirely; 4 = risks FDA: U.S. Food and Drug Administration safety or tolerability concerns. If the FDA decides that a manufacturer has met that burden of proof, it will issue a letter notifying the company that the drug is "approvable." However, approval is dependent on the manufacturer and the FDA developing a mutually acceptable package insert. In fact, the FDA can demand that additional research be performed at the manufacturer's expense before issuing a letter of approval. The package insert is not an exercise instigated by the manufacturer to legally protect itself, but rather part of a federally required process to protect consumers. The presumption is that the prescriber understands the package insert and has effectively communicated the information in it to the patient.
Question 2: What is the basis for what is stated in the package insert?
Only 38% of the medical students who were surveyed indicated that they knew that the information in the package insert is based on clinical trials. Of those, one student specified that the data "may not be of the best quality." In fact, almost every statement in the product insert is supported by specific studies that were conducted for the New Drug Application (NDA) submission process. Hence, the package insert is one of the most evidence-based pieces of literature that can be cited about a specific drug in terms of its uses and risks. The design and execution of the studies that form the basis for the package insert must be done verifiably in accordance with FDA standards. When contents of the package insert were referenced in responses, they nearly always focused on the effects or adverse events of the drug and did not acknowledge indications, dosing guidelines, or other valuable information contained in the document. These responses suggest that the information available in the package insert is not well known to third year medical students, even though they have completed their basic pharmacology training and, in many instances, many of their third year clerkships. Instead, as noted above, the contents of the package insert were generally perceived as limited to adverse effects and potentially influenced by ulterior motives.
There are two exceptions to the fact-based nature of the statements in the product insert. The first is intended to give prescribers some leeway in the use of the drug. Studies are sometimes conducted for a quite limited period of time (e.g., 6 weeks) for an illness for which treatment is typically chronic. In such instances, the package insert may explicitly acknowl-edge this fact and state that, in such instances, the prescriber should periodically re-evaluate the benefits and risks of continuing the medication. The second exception is class warnings, which are issued because one or more drugs in a therapeutic class have been found to cause a serious adverse effect. A new drug in the same therapeutic class will receive that same warning unless the manufacturer/developer does specific studies to prove the agent does not cause that adverse effect. Frequently, such warnings are about infrequent (i.e., < 1/100) or rare (i.e., < 1/1000) but serious adverse events (e.g., agranulocytosis). Due to the low frequency of the occurrence, studies trying to prove whether a new drug does or does not cause the same adverse effect would have to be quite large and hence expensive and time-consuming. For that reason, manufacturers may elect to accept a class warning rather than try to prove that their product does not cause the adverse effect in question.
Question 3: If you are ever sued over the alleged misuse of a drug, why will the package insert generally be introduced as evidence in the case?
Nearly all of the 34 medical students recognized the value of the package insert in providing information about potential adverse events and acknowledged that the prescriber needs to be aware of this information. Again, in their responses to this question, they frequently raised the theme of the manufacturer diverting liability onto the prescriber. Only 15% of the responses referenced one of the most critical Journal of Psychiatric Practice Vol. 20, No. 4 July 2014 289
Psychopharmacology Table 3 . Key facts about the package insert 1. Jointly written by the U.S. Food and Drug Administration and the manufacturer/developer of the specific drug.
2. Highly evidenced-based document with most statements supported by specific clinical and/or preclinical studies.
3. Intent is to provide prescriber with information necessary to use the drug to achieve the optimal outcomes possible by maximizing efficacy as well as safety and tolerability.
4. Limits what the manufacturer/developer can state about the drug.
5. Almost invariably cited in medical malpractice cases involving alleged misuse of a medication.
aspects of medicine-communication between the prescriber and the patient. Not only is it assumed that the prescriber has read and understood the contents of the package insert prior to prescribing a medication to a patient, but also that the risks and benefits have been clearly and effectively communicated to the patient so that the patient can make an informed decision about whether or not to consent to treatment with the medication. Not only is nearly every statement in the package insert backed by highly regulated and scrutinized clinical trials, but it is also a combined statement by the manufacturer and the FDA on the safe and effective use of a medication. Presumably the manufacturer is the foremost expert on the medication, and the FDA is the strongest consumer advocate. What attorney would not use their opinions on his or her client's behalf? The package insert answers two major questions. First, was the medication prescribed at an appropriate dose and frequency for a labeled indication (i.e., an indication for which the drug has been empirically proven effective)? Second, was it prescribed in a manner that is generally safe and well-tolerated (taking into consideration the special needs of the individual patient)?
With that said, many drugs have well documented and accepted "off label" uses that have been discovered over time but that, for a variety of reasonsusually involving money, as noted above-have not been submitted to the FDA for a change in the labeling. These reasons may include a business decision that the market for the new use would not provide a sufficient return on investment to do the necessary studies to make a formal submission for a label change. That decision is often influenced not only by the size of the market but also by how much patent life remains and whether it is a sufficient amount of time to allow for the conduct of the studies needed to support a new filing and generate a return on the new investment. Obviously, there is no financial incentive to pursue a new indication for a drug after the drug's patent has expired and generics are available. Because "off label" uses of approved medications do exist and can provide significant benefit to patients, prescribers need not be limited exclusively to the indications provided in the package insert. However, the prescriber will be held to the "standard of care" threshold in the event of an untoward outcome resulting in a malpractice lawsuit. Although a discussion of standard of care is outside the scope of this column, generally it can be thought of as a consensus concerning how providers for a given population would typically and successfully treat those patients. As noted above, the FDA does not regulate the practice of medicine but rather the practices of pharmaceutical companies.
The results of this survey study underscore the need to revise medical school curricula to provide future prescribers with more education about the importance of the package insert and the relationship between pharmaceutical companies, the U.S. FDA, and prescribers. Prescribers should have an appreciation for the package insert and the complexities involved in its creation ( Table 3 ). The survey described here demonstrated that medical students at two different medical schools did not appreciate several fundamental aspects of the package insert: 1) that it is jointly written by the manufacturer of the specific drug and the FDA, 2) that it is based on data collected from rigorously conducted and externally monitored clinical trials, and 3) the extent of the preclinical and clinical data covered, including pharmacodynamics and pharmacokinetics of the drug, efficacy data, adverse effect data, use of the agent in special high-risk populations (e.g., individuals with renal and hepatic impairment and pregnant women), and how its safety is affected when used in combination with other specific types of drugs. The strength and the breadth of that information explains why knowledge of what is contained in the package insert of a given drug has important legal and patient safety implications for prescribers.
